CYP19A1 and breast carcinoma: The aromatase inhibitors (AIs), e.g., letrozole 1 [18], anastrozole 2 [19], and exemestane [20] (Figure 1a), prevent the stimulating effects of estrogen in breast tissue [19], and they are approved in the treatment of a wide spectrum of breast cancers [21].